Disease-modifying therapies for painful diabetic peripheral neuropathy are urgently needed. A recent study published in Science Translational Medicine demonstrates that monoclonal antibodies that selectively inhibit the activity of matrix metalloproteinase MMP9 alleviate pain, reduce epidermal nerve fibre loss and enhance wound healing in preclinical models of painful neuropathy, highlighting MMP9 as a promising therapeutic target. This is a preview of subscription content, access via your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription Receive 12 print issues and online access Prices may be subject to local taxes which are calculated during checkout Fridman, V. et al.
Advances in the pathophysiology and treatment of diabetic peripheral neuropathy. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain 144, 1632–1645 (2021).
Article PubMed PubMed Central Google Scholar Price, R. et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology 98, 31–43 (2022).
New perspectives in diabetic neuropathy. Neuron 111, 2623–2641 (2023). Article PubMed PubMed Central CAS Google Scholar Eid, S.
Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: predictors of pathology and RAS blockade effects. FASEB J. 35, e21467 (2021). Ozdemir Gultekin, T. et al.
Inflammation, oxidative stress, matrix metalloproteinases and DNA damage in diabetic polyneuropathy and neuropathic pain. Neurol. 17, 1848537 (2026). The role and mechanisms of matrix metalloproteinase-9 in peripheral neuropathic pain.
Extract — continue reading at the source.
